- Home
- ACNB vs REPL Comparison
ACNB vs REPL Comparison
Compare ACNB & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNB
- REPL
- Stock Information
- Founded
- ACNB 1857
- REPL 2015
- Country
- ACNB United States
- REPL United States
- Employees
- ACNB N/A
- REPL N/A
- Industry
- ACNB Major Banks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- ACNB Finance
- REPL Health Care
- Exchange
- ACNB Nasdaq
- REPL Nasdaq
- Market Cap
- ACNB 468.6M
- REPL 547.0M
- IPO Year
- ACNB N/A
- REPL 2018
- Fundamental
- Price
- ACNB $45.48
- REPL $3.29
- Analyst Decision
- ACNB Strong Buy
- REPL Hold
- Analyst Count
- ACNB 3
- REPL 9
- Target Price
- ACNB $50.00
- REPL $7.00
- AVG Volume (30 Days)
- ACNB 19.1K
- REPL 2.1M
- Earning Date
- ACNB 10-23-2025
- REPL 11-11-2025
- Dividend Yield
- ACNB 3.01%
- REPL N/A
- EPS Growth
- ACNB N/A
- REPL N/A
- EPS
- ACNB 2.69
- REPL N/A
- Revenue
- ACNB $123,053,000.00
- REPL N/A
- Revenue This Year
- ACNB $40.40
- REPL N/A
- Revenue Next Year
- ACNB $4.84
- REPL $408.25
- P/E Ratio
- ACNB $16.79
- REPL N/A
- Revenue Growth
- ACNB 15.31
- REPL N/A
- 52 Week Low
- ACNB $35.70
- REPL $2.68
- 52 Week High
- ACNB $50.72
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- ACNB 55.73
- REPL 27.45
- Support Level
- ACNB $44.12
- REPL $5.60
- Resistance Level
- ACNB $46.13
- REPL $5.93
- Average True Range (ATR)
- ACNB 0.83
- REPL 0.40
- MACD
- ACNB -0.09
- REPL -0.11
- Stochastic Oscillator
- ACNB 71.77
- REPL 4.21
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.